Search

Your search keyword '"Maccauro, M."' showing total 219 results
Start Over Author "Maccauro, M."
219 results on '"Maccauro, M."'

2. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Panzuto, F., Maccauro, M., Campana, D., Faggiano, A., Massironi, S., Pusceddu, S., Spada, F., Ferone, D., Modica, R., Grana, C. M., Ferolla, P., Rinzivillo, M., Badalamenti, G., Zatelli, M. C., Gelsomino, F., De Carlo, E., Bartolomei, M., Brizzi, M. P., Cingarlini, S., Versari, A., Fanciulli, G., Arvat, E., Merola, E., Cives, M., Tafuto, S., Baldari, S., and Falconi, M. more...

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

5. NUCLEAR MEDICINE THERAPY WITH 177LU-PSMA-617 AND 177LU-DOTATATE: DOSE RATE PREDICTION AT LATE TIME FROM A SINGLE MEASUREMENT AT EARLY RELEASE TIME: A MULTICENTRIC ITALIAN STUDY

Author

Bagnalasta, M., primary, Brusa, A., additional, Sarnelli, A., additional, Belli, M.L., additional, D’Ambrosio, L., additional, Palmese, V. Pirozzi, additional, Pirozzi, A., additional, Paganelli, G., additional, Lastoria, S., additional, Maccauro, M., additional, Giordano, A., additional, and Chiesa, C., additional more...

Published
2023
Full Text
View/download PDF

6. Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review.

Author

Collarino, A., Fuoco, V., Garganese, G., Pasciuto, T., Koster, E.J. de, Florit, A., Fragomeni, S.M., Zagaria, L., Fragano, A., Martinelli, F., Ditto, A., Seregni, E., Scambia, G., Raspagliesi, F., Rufini, V., Maccauro, M., Collarino, A., Fuoco, V., Garganese, G., Pasciuto, T., Koster, E.J. de, Florit, A., Fragomeni, S.M., Zagaria, L., Fragano, A., Martinelli, F., Ditto, A., Seregni, E., Scambia, G., Raspagliesi, F., Rufini, V., and Maccauro, M. more...

Abstract

Item does not contain fulltext, OBJECTIVE: This multicenter study aimed to investigate the role of preoperative lymphatic mapping and sentinel node biopsy (SNB) as well as the impact of negative SNB on loco-regional control and survival in vulvar melanoma patients with clinically negative nodes (cN0). METHODS: Patients who had a proven vulvar melanoma with a Breslow thickness of 1-4 mm, cN0 and underwent a preoperative lymphatic mapping followed by SNB between July 2013 and March 2021 were retrospectively included. Groin recurrence and mortality rate were calculated as absolute and relative frequency. Disease-free survival (DFS) and overall survival (OS) were assessed by the Kaplan-Meier method. We provided a systematic review, searching among PubMed/Medline and Embase libraries. A total of 6 studies were identified (48 patients). RESULTS: A total of 18 women were included. Preoperative planar images showed 51 SNs in 28 groins. Additional SPECT/CT images were acquired in 5/18 cases; SNs were identified pre- and intra-operatively in all cases. A total of 65 SNs were excised from 28 groins. A total of 13/18 (72.2%) patients (21/28 groins, 75%) had negative SNs with no groin recurrences and 12/13 (92.3%) were still alive at last follow-up. Five out of the 18 (27.8%) patients (7/28 groins, 25%) had positive SNs, 2/5 (40%) patients died of cancer after 26.2 and 33.8 months, respectively. The median DFS and OS for the entire cohort were 17.9 months (95% CI, 10.3-19.9) and 65.0 months (95% CI, 26.2-infinite), respectively. The probability of DFS and OS at 3 years were 15.5% (95% CI, 2.6-38.7) and 64.3% (95% CI, 15.5-90.2), respectively. CONCLUSIONS: The use of preoperative lymphatic mapping followed by SNB permits a precise and minimally invasive surgical approach in cN0 vulvar melanoma patients. Negative SNB is associated with low risk of groin relapse and good survival. more...

Published
2023

8. Bilateral inguinal lymph-node dissection versus unilateral inguinal lymph-node dissection and contralateral dynamic sentinel node biopsy in clinical N1 squamous cell carcinoma of the penis

Author

Nazzani, S., primary, Catanzaro, M., additional, Macchi, A., additional, Torelli, T., additional, Stagni, S., additional, Biasoni, D., additional, Lorusso, V., additional, Darisi, R., additional, Lanocita, R., additional, Cascella, T., additional, Maccauro, M., additional, Lorenzoni, A., additional, Cattaneo, L., additional, Montanari, E., additional, Salvioni, R., additional, and Nicolai, N., additional more...

Published
2022
Full Text
View/download PDF

9. Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

Author

Chiesa, C., Mira, M., Maccauro, M., Spreafico, C., Romito, R., Morosi, C., Camerini, T., Carrara, M., Pellizzari, S., Negri, A., Aliberti, G., Sposito, C., Bhoori, S., Facciorusso, A., Civelli, E., Lanocita, R., Padovano, B., Migliorisi, M., De Nile, M. C., Seregni, E., Marchianò, A., Crippa, F., and Mazzaferro, V. more...

Published
2015
Full Text
View/download PDF

11. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

Author

Ricci, C., Pusceddu, S., Prinzi, N., Tafuto, S., Ibrahim, T., Filice, A., Brizzi, M. P., Panzuto, F., Baldari, S., Grana, C. M., Campana, D., Davi, M. V., Giuffrida, D., Zatelli, M. C., Partelli, S., Razzore, P., Marconcini, R., Massironi, S., Gelsomino, F., Faggiano, A., Giannetta, E., Bajetta, E., Grimaldi, F., Cives, M., Cirillo, F., Perfetti, V., Corti, F., Giacomelli, L., Porcu, L., Di Maio, M., Seregni, E., Maccauro, M., Lastoria, S., Bongiovanni, A., Versari, A., Persano, I., Rinzivillo, M., Pignata, S. A., Rocca, P. A., Lamberti, G., Cingarlini, S., Puliafito, I., Ambrosio, M. R., Zanata, I., Bracigliano, A., Severi, S., Spada, F., Andreasi, V., Modica, R., Scalorbi, F., Milione, M., Sabella, G., Coppa, J., Casadei, R., Di Bartolomeo, M., Falconi, M., De Braud, F., Pusceddu, Sara, Prinzi, Natalie, Tafuto, Salvatore, Ibrahim, Toni, Filice, Angelina, Brizzi, Maria Pia, Panzuto, Francesco, Baldari, Sergio, Grana, Chiara M., Campana, Davide, Davì, Maria Vittoria, Giuffrida, Dario, Zatelli, Maria Chiara, Partelli, Stefano, Razzore, Paola, Marconcini, Riccardo, Massironi, Sara, Gelsomino, Fabio, Faggiano, Antongiulio, Giannetta, Elisa, Bajetta, Emilio, Grimaldi, Franco, Cives, Mauro, Cirillo, Fernando, Perfetti, Vittorio, Corti, Francesca, Ricci, Claudio, Giacomelli, Luca, Porcu, Luca, Di Maio, Massimo, Seregni, Ettore, Maccauro, Marco, Lastoria, Secondo, Bongiovanni, Alberto, Versari, Annibale, Persano, Irene, Rinzivillo, Maria, Pignata, Salvatore Antonio, Rocca, Paola Anna, Lamberti, Giuseppe, Cingarlini, Sara, Puliafito, Ivana, Ambrosio, Maria Rosaria, Zanata, Isabella, Bracigliano, Alessandra, Severi, Stefano, Spada, Francesca, Andreasi, Valentina, Modica, Roberta, Scalorbi, Federica, Milione, Massimo, Sabella, Giovanna, Coppa, Jorgelina, Casadei, Riccardo, Di Bartolomeo, Maria, Falconi, Massimo, de Braud, Filippo, Grana, Chiara M, and Davi, Maria Vittoria more...

Subjects
Male, Radiotherapy, Receptors, Peptide, General Medicine, sequence, Middle Aged, peptide receptors radionuclide therapy, everolimus, chemotherapy, Progression-Free Survival, NO, Peptide Receptor Radionuclide Therapy, Pancreatic Neoplasms, Neuroendocrine Tumors, receptor radionuclide therapy, enteropancreatic neuroendocrine tumors, progression free survival, Receptors, Peptide, Humans, Female, LS4_3, neuroendocrine tumors, sequence, everolimus, Retrospective Studies
Abstract

Importance: Data about the optimal timing for the initiation of peptide receptor radionuclide therapy (PRRT) for advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. Objective: To evaluate the association of upfront PRRT vs upfront chemotherapy or targeted therapy with progression-free survival (PFS) among patients with advanced enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues (SSAs). Design, setting, and participants: This retrospective, multicenter cohort study analyzed the clinical records from 25 Italian oncology centers for patients aged 18 years or older who had unresectable, locally advanced or metastatic, well-differentiated, grades 1 to 3 enteropancreatic neuroendocrine tumors and received either PRRT or chemotherapy or targeted therapy after experiencing disease progression after treatment with SSAs between January 24, 2000, and July 1, 2020. Propensity score matching was done to minimize the selection bias. Exposures: Upfront PRRT or upfront chemotherapy or targeted therapy. Main outcomes and measures: The main outcome was the difference in PFS among patients who received upfront PRRT vs among those who received upfront chemotherapy or targeted therapy. A secondary outcome was the difference in overall survival between these groups. Hazard ratios (HRs) were fitted in a multivariable Cox proportional hazards regression model to adjust for relevant factors associated with PFS and were corrected for interaction with these factors. Results: Of 508 evaluated patients (mean ([SD] age, 55.7 [0.5] years; 278 [54.7%] were male), 329 (64.8%) received upfront PRRT and 179 (35.2%) received upfront chemotherapy or targeted therapy. The matched group included 222 patients (124 [55.9%] male; mean [SD] age, 56.1 [0.8] years), with 111 in each treatment group. Median PFS was longer in the PRRT group than in the chemotherapy or targeted therapy group in the unmatched (2.5 years [95% CI, 2.3-3.0 years] vs 0.7 years [95% CI, 0.5-1.0 years]; HR, 0.35 [95% CI, 0.28-0.44; P more...

Published
2022

14. Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship

Author

Chiesa, C., primary, Mira, M., additional, Bhoori, S., additional, Bormolini, G., additional, Maccauro, M., additional, Spreafico, C., additional, Cascella, T., additional, Cavallo, A., additional, De Nile, M.C., additional, Mazzaglia, S., additional, Capozza, A., additional, Tagliabue, G., additional, Brusa, A., additional, Marchianò, A., additional, Seregni, E., additional, and Mazzaferro, V., additional more...

Published
2021
Full Text
View/download PDF

20. 1105P Predictive factors of adverse events onset in GEPNET patients treated with PRRT

Author

Scalorbi, F., primary, Argiroffi, G., additional, Lorenzoni, A., additional, Baccini, M., additional, Gherardini, L., additional, Fuoco, V., additional, Prinzi, N., additional, Pusceddu, S., additional, Calareso, G., additional, Garanzini, E., additional, Centonze, G., additional, Milione, M., additional, Chiesa, C., additional, Seregni, E., additional, and Maccauro, M., additional more...

Published
2021
Full Text
View/download PDF

21. Current Status and Future Direction of Hepatic Radioembolisation

Author

Researchgr. Nucleaire Geneeskunde, Cancer, MS Radiologie, Onderzoek Beeld, Fysica Radiologie, Other research (not in main researchprogram), Brain, Alsultan, A A, Braat, A J A T, Smits, M L J, Barentsz, M W, Bastiaannet, R, Bruijnen, R C G, de Keizer, B, de Jong, H W A M, Lam, M G E H, Maccauro, M, Chiesa, C, Researchgr. Nucleaire Geneeskunde, Cancer, MS Radiologie, Onderzoek Beeld, Fysica Radiologie, Other research (not in main researchprogram), Brain, Alsultan, A A, Braat, A J A T, Smits, M L J, Barentsz, M W, Bastiaannet, R, Bruijnen, R C G, de Keizer, B, de Jong, H W A M, Lam, M G E H, Maccauro, M, and Chiesa, C more...

Published
2021

23. Dynamic sentinel node biopsy for clinical N0 squamous cell penile carcinoma: a large, contemporary analysis

Author

Catanzaro, M., primary, Nazzani, S., additional, Torelli, T., additional, Aceti, A., additional, Macchi, A., additional, Tesone, A., additional, Stagni, S., additional, Maccauro, M., additional, Colecchia, M., additional, Lanocita, R., additional, Cascella, T., additional, Necchi, A., additional, Raggi, D., additional, Giannatempo, P., additional, Biasoni, D., additional, Salvioni, R., additional, and Nicolai, N., additional more...

Published
2020
Full Text
View/download PDF

24. Dynamic sentinel node biopsy versus observation in clinical N0 penile squamous cell carcinoma: a large tertiary national referral center experience

Author

Nazzani, S., primary, Catanzaro, M., additional, Macchi, A., additional, Tesone, A., additional, Aceti, A., additional, Torelli, T., additional, Stagni, S., additional, Maccauro, M., additional, Colecchia, M., additional, Lanocita, R., additional, Cascella, T., additional, Piva, L., additional, Biasoni, D., additional, Carmignani, L., additional, Montanari, E., additional, Salvioni, R., additional, and Nicolai, N., additional more...

Published
2020
Full Text
View/download PDF

26. Determinants of inguinal lymph node involvement and predicted rates of inguinal nodal disease in clinical N0 penile squamous cell carcinoma patients

Author

Catanzaro, M., primary, Nazzani, S., additional, Macchi, A., additional, Aceti, A., additional, Tesone, A., additional, Stagni, S., additional, Torelli, T., additional, Colecchia, M., additional, Maccauro, M., additional, Lanocita, R., additional, Cascella, T., additional, Biasoni, D., additional, Salvioni, R., additional, and Nicolai, N., additional more...

Published
2020
Full Text
View/download PDF

27. 1183P Sequential PRRT and SIRT: Evaluation of safety, toxicity and best sequence treatment in liver dominant GEPNETs

Author

Scalorbi, F., primary, Lorenzoni, A., additional, Mazzaglia, S., additional, Garanzini, E., additional, Chiesa, C., additional, Aliberti, G., additional, Argiroffi, G., additional, Pusceddu, S., additional, Prinzi, N., additional, Spreafico, C., additional, Centonze, G., additional, Coppa, J., additional, Marchianò, A., additional, Milione, M., additional, Mazzaferro, V., additional, Seregni, E., additional, and Maccauro, M., additional more...

Published
2020
Full Text
View/download PDF

28. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

Author

Panzuto, F., primary, Maccauro, M., additional, Campana, D., additional, Faggiano, A., additional, Massironi, S., additional, Pusceddu, S., additional, Spada, F., additional, Ferone, D., additional, Modica, R., additional, Grana, C. M., additional, Ferolla, P., additional, Rinzivillo, M., additional, Badalamenti, G., additional, Zatelli, M. C., additional, Gelsomino, F., additional, De Carlo, E., additional, Bartolomei, M., additional, Brizzi, M. P., additional, Cingarlini, S., additional, Versari, A., additional, Fanciulli, G., additional, Arvat, E., additional, Merola, E., additional, Cives, M., additional, Tafuto, S., additional, Baldari, S., additional, and Falconi, M., additional more...

Published
2020
Full Text
View/download PDF

37. 85. Treatment of hepatocarcinoma with 90Y glass microspheres: Safety and indication of prolonged overall survival thanks to two compartment dosimetric treatment planning

Author

Chiesa, C., primary, Mira, M., additional, Maccauro, M., additional, Spreafico, C., additional, Cascella, T., additional, Sposito, C., additional, Bhoori, S., additional, De Nile, M.C., additional, Seregni, E., additional, Marchianò, A., additional, Crippa, F., additional, and Mazzaferro, V., additional more...

Published
2018
Full Text
View/download PDF

38. The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)

Author

Prinzi, N., primary, Seregni, E., additional, Raimondi, A., additional, Maccauro, M., additional, Corti, F., additional, Lo Russo, G., additional, Nichetti, F., additional, Torchio, M., additional, Coppa, J., additional, Peverelli, G., additional, Pagani, F., additional, Di Bartolomeo, M., additional, Mazzaferro, V., additional, de Braud, F., additional, and Pusceddu, S., additional more...

Published
2018
Full Text
View/download PDF

44. 1324P - The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)

Author

Prinzi, N., Seregni, E., Raimondi, A., Maccauro, M., Corti, F., Lo Russo, G., Nichetti, F., Torchio, M., Coppa, J., Peverelli, G., Pagani, F., Di Bartolomeo, M., Mazzaferro, V., de Braud, F., and Pusceddu, S. more...

Published
2018
Full Text
View/download PDF

46. Truly dosimetric treatment planning with 99m-TC MAA SPECT prolonged overall survival in radioembolization of hepatocarcinoma with 90-y glass microspheres

Author

Chiesa, C., primary, Mira, M., additional, Maccauro, M., additional, Facciorusso, A., additional, Spreafico, C., additional, Romito, R., additional, Sposito, C., additional, Brusa, A., additional, Padovano, B., additional, Migliorisi, M., additional, Marchianò, A., additional, Crippa, F., additional, and Mazzaferro, V., additional more...

Published
2016
Full Text
View/download PDF

47. Treatment with tandem [(90)Y]DOTA-TATE an [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results

Author

Seregni E, Maccauro M, Angela Coliva, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, and Bombardieri E

Subjects
Adult, Male, Radiotherapy, Middle Aged, Octreotide, Treatment Outcome, Receptors, Organometallic Compounds, Humans, Somostatin, Drug Therapy, Combination, Neuroendocrine tumors, Radiometry, Aged
Abstract

AIM: Neuroendocrine tumors over-express somatostatin receptors and literature data have demonstrated the efficacy of the peptide receptor radionuclide therapy with somatostatin analogues labelled with high activities of b-emitting radioisotopes, such as (90)Y and (177)Lu. Yttrium-90 is a pure high energy b-emitter while (177)Lu is a b/g emitter of medium energy. We decided to evaluate an original tandem treatment based on administration of radiolabeled [DOTA(0),Tyr(3)]octreotate (DOTA-TATE) alternating (177)Lu and 90Y. Aim of this study was to evaluate the feasibility, the efficacy and the toxicity of this treatment in neuroendocrine tumors expressing somatostatin receptors relapsed or refractory to conventional therapies. METHODS: Patients were treated with four therapeutic cycles alternating [(177)Lu]DOTA-TATE (5.55 GBq) and [(90)Y]DOTA-TATE (2.6 GBq). Dosimetric evaluation after administration of [(177)Lu]DOTA-TATE allows to calculate the absorbed doses in healthy organs. Blood samples were collected at 5 min, 1, 6, 24, 48, 72, 96 h and scintigraphy was performed once a day for four days after administration. Toxicity was evaluated considering hematological parameters and renal toxicity was evaluated also by the glomerular filtration rate (GFR). Efficacy related with RECIST criteria. RESULTS: Up to now 26 patients entered the study and 16 patients completed all cycles. Treatment was well tolerated with no adverse event registered. No damage to healthy organs was revealed in accordance with the calculated absorbed doses. We had a partial response in 10/15 patients evaluated three months after the fourth treatment. CONCLUSIONS: Up to now only a few patients participated in and concluded this study; preliminary results are encouraging and indicate the feasibility of the study. more...

Published
2010

49. Analisi recettoriale in macroadenomi ipofisari misti

Author

RAMBALDI, Pier Francesco, Cascini GL, Pansa N, Scarano M, Maccauro M, Scillirò F, Mansi L., Rambaldi, Pier Francesco, Cascini, Gl, Pansa, N, Scarano, M, Maccauro, M, Scillirò, F, and Mansi, L.

Published
1999